In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 14.59% ...

Piper Sandler analyst Scott Siefers maintained a Hold rating on Bank of America (BAC – Research Report) today and set a price target of $49.00.

Piper Sandler’s price objective ... from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Barclays boosted their price target on shares ...

ChampionX Corp (CHX) stock saw a modest uptick, ending the day at $31.21 which represents a slight increase of $2.06 or 7.07% from the prior close of $29.15. The stock opened at $29.52 and touched a ...

Piper Sandler adjusted its outlook on Charles Schwab Corp (BVMF:SCHW34). (NYSE: SCHW) shares, increasing the price target to $78 from $70 while maintaining a Neutral rating. The decision followed ...

Barclays (LON:BARC) made adjustments to its outlook on Nutrien shares (NYSE:NTR), downgrading the stock rating from ...

But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. Long term Piper Sandler Companies (NYSE:PIPR) shareholders would be well aware ...

But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. Long term Piper Sandler Companies (NYSE:PIPR) shareholders would be well aware of ...